Navigation Links
Analyst Available to Comment on New JUPITER Study That Shows AstraZeneca's Crestor Significantly Reduces CV Risk
Date:11/19/2008

WALTHAM, Mass., Nov. 19 /PRNewswire/ --Graeme GreenPh.D, analyst at Decision Resources, is available to discuss the results of the JUPITER study presented at the American Heart Association (AHA) Scientific Sessions this month.

The results of the 17,802-patient trial demonstrated AstraZeneca's Crestor to be effective at cutting the risk of heart attack and death among patients who seemed healthy but showed high levels of high-sensitivity C-reactive protein (hsCRP). In the study, those who had normal LDL cholesterol levels, but who were identified as being at increased cardiovascular risk due to elevated hsCRP, received either Crestor or placebo. Findings showed that those who took Crestor had a 44 percent reduction in the occurrence of a first major cardiovascular event and a 47 percent reduction in the combined risk of stroke, heart attack or cardiovascular death, compared with those who took placebo. The data also indicated that total mortality in the Crestor group was reduced by 20 percent versus the placebo group.

Dr. Green is available to discuss:

  • The initial reaction from thought leaders at the AHA in response to the JUPITER study
  • How the positive messaging and heightened patient awareness for Crestor after the JUPITER trial will boost sales of the brand in the near term
  • The potential for changes to Crestor's label, treatment guidelines and MCO reimbursement status, and how these changes will impact Crestor's revenue
  • The place of hsCRP testing in routine clinical practice
  • Crestor-specific effects vs. statin class effects

To speak with Dr. Green, please contact Heather Hilty at 781-296-2536 or hhilty@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Heather Hilty                       Elizabeth Marshall
    Decision Resources                  Decision Resources, Inc.
    781-296-2536                        781-296-2563
    hhilty@dresources.com               emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
2. AMN Healthcare Services to Host Analyst Day on Tuesday, September 18, 2007
3. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
4. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
5. Perrigo Company to Host Analyst Meeting on September 18, 2007
6. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
7. Par Invites Public to Listen to Webcast of its September 28 Analysts Meeting
8. Par Pharmaceutical Provides Summary of Analyst/Investor Day
9. Accuray to Webcast Senior Management Presentations at Analyst Day Event
10. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007
11. FBR Capital Markets Hires Senior Healthcare Analyst
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... , ... An April 24th article on Yahoo! Beauty discusses the case of Jessica ... a weight loss surgery. The woman, declaring “I will not hate my body anymore!” posted ... dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers its patients ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for ... Care Association of America (HCAOA). This agreement allows HCAOA members to receive special ... as discounts on Accreditation University (AU) educational resources that help prepare HCAOA members ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, ... of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create and edit their ... reporting process and provides a familiar interface that does not require additional training ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. ... GlycoMark test throughout the Northeast U.S. , GlycoMark is the only clinically ... GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
Breaking Medicine Technology: